Agilis Biotherapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
245 1st St Ste 1800, Cambridge, Massachu...Phone Number
(339) 440-5818Website
www.agilisbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Agilis Biotherapeutics
Agilis is advancing innovative gene therapies designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system. Agilis' gene therapies are engineered to impart sustainable clinical benefits by inducing persistent expression of a therapeutic gene through precise targeting and restoration of lost gene function to achieve long-term efficacy. Agilis' rare disease programs are focused on gene therapy for AADC deficiency, Friedreich ataxia and Angelman syndrome, rare genetic diseases that include neurological deficits and result in physically debilitating conditions. The Company is preparing a BLA for its AADC deficiency investigational gene therapy and anticipates approval in 2019.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Agilis Biotherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Agilis Biotherapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Agilis Biotherapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Agilis Biotherapeutics
Click to see if Agilis Biotherapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Agilis Biotherapeutics has new funding data
Check if Agilis Biotherapeutics has recently received funding, and reach out quickly before it becomes old news!
Agilis Biotherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Agilis Biotherapeutics launches new products
Recommended Actions
Find VP level buyers at Agilis Biotherapeutics
Find more new buyers
Compare Similar Companies to Agilis Biotherapeutics
Compare insights from companies similar to Agilis Biotherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Agilis Biotherapeutics
<$5M
11-50
Private
$20.7M
2013
N/A
Company Profile Activity
Activity Insights
Agilis Biotherapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Agilis Biotherapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Agilis Biotherapeutics.
Agilis Biotherapeutics financials insights
Gather financial insights about Agilis Biotherapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Private Equity
$8M
2017
Private Equity
$12.7M
Agilis Biotherapeutics Tech Stack
A closer look at the technologies used by Agilis Biotherapeutics
Agilis Biotherapeutics News & Media
Agilis Biotherapeutics Announces Data Presentations on AADC Deficiency at the American Society of Gene and Cell Therapy 2018 Annual Meeting
LYNNFIELD, Mass.--(BUSINESS WIRE)--#AADC--Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced that multiple abstracts by its collaborators and partners were selected for presentation at the American Society of Gene and Cell Therapy (ASGCT) taking place May 16-19, 2018, in Chicago, IL. Agilis’ gene therapy candidate, AGIL-AADC, is an investigational therapeutic adminiAgilis Biotherapeutics Presents on Gene Therapy Pricing Strategies at the 2nd Annual Gene Therapy for Rare Disorders Summit
LYNNFIELD, Mass.--(BUSINESS WIRE)--#AADC--Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that Markus Peters, Ph.D., Agilis Chief Commercial Officer (CCO), will give a presentation on the topic “Evaluating Potential Pricing Strategies for Gene Therapies” and participate in the panel discussion “Pricing, Reimbursement & Market Access Considerations” during tAgilis Biotherapeutics Presents Platform Paper on AADC Deficiency Gene Therapy at American Academy of Neurology Annual Meeting
LYNNFIELD, Mass.--(BUSINESS WIRE)--#AADC--Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced that Agilis Chief Medical Officer, Kirsten Gruis, M.D., will present a platform paper entitled “Gene Therapy in Children with AADC Deficiency with AGIL-AADC Leads to De Novo Dopamine Production and Sustained Improvement in Motor Milestones over 5 Years,” at the American AcadAgilis Biotherapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--#Agilis--Agilis Biotherapeutics, Inc. (Agilis), a clinical-stage biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that Mark Pykett, VMD, PhD, Agilis President and CEO, will speak to the investment community at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will be held on January 9, 2018 at 10:30 am PST. About Agilis Bioth
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Agilis Biotherapeutics
Sign Up For FreeTo access detailed company insights
Agilis is advancing innovative gene therapies designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system. Agilis' gene therapies are engineered to impart sustainable clinical benefits by inducing persistent expression of a therapeutic gene through precise targetin... Read More
